Skip to content

Trial Summary

This is a phase 1b open-label, multi-centre, dose escalation study of Pexa-Vec (Thyidine Kinase- deactivated vaccinia virus plus GM-CSF) in combination with REGN2810 (anti-PD-1) in patients with metastatic or unresectable renal cell carcinoma (RCC).



ACTRN/NCT /ethics:


Scientific title:

A study of recombinant vaccinia virus in combination with REGN2810 for renal cell carcinoma

Sponsor / Cooperative group:

SillaJen, Inc.

Trial & Patient Characteristics

Cancer TypeKidney
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream Renal Cell Carcinoma
Cancer StageMetastatic or Widespread
Anticipated Start Date2018-06-07
Anticipated End Date2020-09-01

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Phone08 8204 4830
Principal Investigator-
Recruitment StatusRecruiting